转移性割敏感前列腺癌的治疗强化:加拿大阿尔伯塔省的一项现实研究
Steven M Yip1, Winson Y Cheung2,3, Armen Aprikian4
1Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.
Future oncology (London, England)
|March 24, 2025
概括
加拿大的转移性割敏感前列腺癌 (mCSPC) 的治疗强化率低于最佳水平. 老年患者和患有复发性mCSPC的患者不太可能接受TI,这表明需要改善获得先进疗法的机会.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 医疗保健服务研究 医疗服务研究
背景情况:
- 转移性割敏感前列腺癌 (mCSPC) 需要及时有效地加强治疗.
- 雄激素受体通路抑制剂 (ARPI) 和多赛是mCSPC治疗强化关键选择.
研究的目的:
- 评估目前在加拿大各地mCSPC患者的治疗强化 (TI) 的利用情况.
- 确定影响mCSPCITIT战略的时机和选择的因素.
主要方法:
- 来自阿尔伯塔前列腺癌研究倡议数据库的431名mCSPC患者的回顾性分析 (2014年7月-2022年3月).
- 评估接受TI的患者比例,TI的时间以及相关的人口和临床因素.
- 对TI模式和治疗选择决定因素的探索性分析.
主要成果:
- 总体而言,42%的mCSPC患者接受了TI,其中65%在3个月内开始接受TI.
- 患有复发性mCSPC和75岁以上的患者接受TI的可能性较小.
- 多重转移部位和骨转移与接受TI的可能性更高有关,主要是与ARPI (75%) 相关.
结论:
- 加拿大的mCSPC治疗强化率低于最佳水平,特别是在老年人和患有复发性疾病的人群中.
- 在治疗不足的mCSPC人群中优先考虑TI可能会改善患者的治疗结果.
- 对优化TI策略的进一步研究对于不同的mCSPC患者群体是有必要的.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...